| abstract |
The present invention provides an anti-FcyRIIB antibody, which significantly increases ITIM phosphorylation of FcyRIIB in comparison with conventional antibodies, and is used for therapeutic or prophylactic treatment of autoimmune diseases. Can be used for this purpose. The antibody is (i) an H-CDR1 sequence 60% or more identical to the H-CDR1 sequence shown in SEQ ID NO: 20, and (ii) 36% or more identical to the H-CDR2 sequence shown in SEQ ID NO: 21 H-CDR2 sequence, (iii) H-CDR3 sequence 50% or more identical to the H-CDR3 sequence shown in SEQ ID NO: 22, (iv) 64% or more identical to the L-CDR1 sequence shown in SEQ ID NO: 23 (V) an L-CDR2 sequence 29% or more identical to the L-CDR2 sequence shown in SEQ ID NO: 24, and (vi) 78% to the L-CDR3 sequence shown in SEQ ID NO: 25 An L-CDR3 sequence that is identical to the above. |